Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 17/20 | 0.56 |
| ▸ | CCR3 | P51677 | 17/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31128128 | 0.85 | SLC6A2 (0.69) | HRH1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL942585 | 0.85 | SLC6A2 (0.69) | HRH1SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL31381194 | 0.84 | SLC6A2 (0.67) | HRH1SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL4107468 | 0.84 | SLC6A2 (0.67) | HRH1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL6570615 | 0.83 | HRH1 (0.56) | HRH1CCR3KCNH2HRH3 | |
| SCHEMBL4718730 | 0.81 | HRH3 (0.54) | HRH1CCR3KCNH2HRH3 | |
| SCHEMBL4154387 | 0.80 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL5468103 | 0.80 | SLC6A2 (0.61) | HRH1KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5409384 | 0.79 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL5419495 | 0.79 | HRH1 (0.63) | HRH1CCR3KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276141-A1 | Preparation of Pharmaceutical Salts of [1,4] - Bipiperidine | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | claimed |
| EP-1682139-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF 1, 4 - BIPIPERIDINE | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044268-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF [1, 4] - BIPIPERIDINE | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | claimed |
| US-7482363-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1493743-B1 | Substituted bipiperidine intermediates and derivatives thereof | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1487817-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| US-20070276141-A1 | Preparation of Pharmaceutical Salts of [1,4] - Bipiperidine | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2003078421-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | WO | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| WO-2003004487-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20070276141-A1 | Preparation of Pharmaceutical Salts of [1,4] - Bipiperidine | CCR3, CCR1, CCR4 | HRH1 55/4885CCR3 1/4885KCNH2 986/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885CCR3 1/4885KCNH2 4084/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 38/4885CCR3 1/4885KCNH2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.